Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:

Lexicon Pharmaceutcl (LXRX)

Lexicon Pharmaceutcl (LXRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Lexicon to Present Preclinical IN VIVO Efficacy Data Demonstrating Ability of New Investigational Compound to Enhance and Maintain Semaglutide-Promoted Weight Loss GlobeNewswire - Mon Nov 4, 7:00AM CST

LXRX : 1.2050 (-1.23%)
Lexicon Announces Outcome of FDA Advisory Committee for Zynquista™ (sotagliflozin) as an Adjunct to Insulin Therapy for Glycemic Control in Adults with Type 1 Diabetes and Chronic Kidney Disease GlobeNewswire - Thu Oct 31, 5:54PM CDT

LXRX : 1.2050 (-1.23%)
New Analysis of Phase 3 Data Demonstrating Renal Protective Benefits of Sotagliflozin to be Presented at ASN Kidney Week 2024 GlobeNewswire - Wed Oct 23, 8:00AM CDT

LXRX : 1.2050 (-1.23%)
Lexicon Announces Completion of Screening in Phase 2B Progress Study of LX9211 in Diabetic Peripheral Neuropathic Pain (DPNP) GlobeNewswire - Tue Oct 22, 7:00AM CDT

LXRX : 1.2050 (-1.23%)
Lexicon Announces Exclusive Licensing Agreement With Viatris for Sotagliflozin in All Markets Outside of the U.S. and Europe GlobeNewswire - Wed Oct 16, 3:35PM CDT

LXRX : 1.2050 (-1.23%)
VTRS : 11.45 (-1.46%)
Lexicon: Q2 Earnings Snapshot AP - Thu Aug 1, 3:12PM CDT

Lexicon: Q2 Earnings Snapshot

LXRX : 1.2050 (-1.23%)
Lexicon: Q1 Earnings Snapshot AP - Thu May 2, 4:00PM CDT

Lexicon: Q1 Earnings Snapshot

LXRX : 1.2050 (-1.23%)
Lexicon: Q4 Earnings Snapshot AP - Mon Mar 11, 6:34AM CDT

Lexicon: Q4 Earnings Snapshot

LXRX : 1.2050 (-1.23%)
3 Under-the-Radar Stocks With 340% to 762% Upside in 2024, According to Select Wall Street Analysts Motley Fool - Wed Jan 31, 4:06AM CST

If a trio of Wall Street analysts is correct, three lesser-known stocks could skyrocket in the new year.

COMP : 6.66 (+3.90%)
PLUG : 2.51 (+20.10%)
LXRX : 1.2050 (-1.23%)
NVAX : 9.12 (-2.46%)
3 of the Fastest-Growing Stocks on the Planet in 2024 Motley Fool - Tue Jan 23, 4:21AM CST

These hypergrowth stocks are expected to deliver sales growth of up to 1,106% in the new year.

COMP : 6.66 (+3.90%)
LCID : 2.24 (+1.82%)
LXRX : 1.2050 (-1.23%)
NKLA : 3.29 (-12.38%)

Barchart Exclusives

Is This High-Yield Dividend Stock a Buy After Earnings? Barchart - 1 hour ago
This pharmaceutical giant's Q3 numbers came in ahead of Street estimates. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot